TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05070416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lithium disilicate crowns
Description: The study population is separated in two groups. The teeth will be etched in total etch mode with 37% phosphoric acid (Total Etch, Ivoclar Vivadent AG). After the application of Adhese Universal-adhesive (Ivoclar Vivadent AG), MultiCore Flow (Ivoclar Vivadent AG) will be applied. The crowns will be polished, then etched with IPS Ceramic Etching Gel (Ivoclar Vivadent AG) and conditioned with Monobond Plus (Ivoclar Vivadent AG). The crowns will be luted as described for group 1 or 2. A final intraoral polishing step will be done with OptraGloss (Ivoclar Vivadent AG). All required light-curing steps are conducted with Bluephase G4 (Ivoclar Vivadent AG).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lithium disilicate crowns
Description: The study population is separated in two groups. The teeth will be etched in total etch mode with 37% phosphoric acid (Total Etch, Ivoclar Vivadent AG). After the application of Adhese Universal-adhesive (Ivoclar Vivadent AG), MultiCore Flow (Ivoclar Vivadent AG) will be applied. The crowns will be polished, then etched with IPS Ceramic Etching Gel (Ivoclar Vivadent AG) and conditioned with Monobond Plus (Ivoclar Vivadent AG). The crowns will be luted as described for group 1 or 2. A final intraoral polishing step will be done with OptraGloss (Ivoclar Vivadent AG). All required light-curing steps are conducted with Bluephase G4 (Ivoclar Vivadent AG).
Study: NCT06138028

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）
Description: TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）for 4 cycles, then irradiation of the residual lesions for 50Gy/2Gy/25f. After complete irradiation, sintilimab is administered every 21 days a cycle for additional 13 cycles.
Study: NCT04759677

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise with active video games
Description: 45-minute exercise in which individuals played pre-selected games from Nintendo Wii while keeping in mind their functional level, skills and needs. Four Nintendo Wii games were chosen: Island Cycling, Tilt Table Balance Board, Soccer Heading and Boxing. Each and every individual played these given four games consecutively in one session.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise with active video games
Description: 45-minute exercise in which individuals played pre-selected games from Nintendo Wii while keeping in mind their functional level, skills and needs. Four Nintendo Wii games were chosen: Island Cycling, Tilt Table Balance Board, Soccer Heading and Boxing. Each and every individual played these given four games consecutively in one session.
Study: NCT05493540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen oral suspension
Description: The medical treatment group will receive oral Ibuprofen with conservative therapy in the form of fluid restriction, Positive End Expiratory Pressure (PEEP), and/or diuretics~An additional course of Ibuprofen may be offered if there is:~1. Moderate/Severe PDA on Echocardiography~2. Prolonged ventilation or Increased ventilatory setting~3. Prolonged use of inotropes or vasopressors or escalating dose~   * Another form of treatment may be offered if the patient developed side effects from Ibuprofen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Group will receive Oral Placebo and Conservative therapy in the form of fluid restriction, PEEP, and/or diuretics~An Open-label option might be offered if there are concerns by attending physicians over the poor patient condition that might be attributed to persistent PDA:~1. Prolonged Ventilation or Escalating Ventilatory Setting~2. Prolonged Use Of Inotropes or Vasopressors or escalation of Doses~Rescue therapy in the form of a course of oral ibuprofen may be offered:~1. After 5 days of recruitment~2. Moderate/Severe PDA on Echocardiography~3. Prolonged ventilation or Increased ventilatory setting~4. Prolonged use of inotropes or vasopressors or escalating dose - Another form of treatment may be offered if the patient developed side effects from Ibuprofen
Study: NCT05883085

Intervention type: DRUG
Group type: OTHER
Intervention: Anlotinib hydrochloride
Description: Patients receive anlotinib hydrochloride 8-12mg orally once daily on days 1-14. Courses repeat every 21 days
Study: NCT06511440

Intervention type: DEVICE
Intervention: Vision-700
Description: OCT machines used for diagnostic purposes
Study: NCT04818541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PPCI
Description: Closure of the femoral access site with PerQseal device at the end of the PPCI index procedure and removal of the Impella pump.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiogenic shock
Description: Closure of the femoral access site with PerQseal device after removal of the Impella pump.
Study: NCT06446466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF ON-OFF
Description: In the experimental condition PEMF ON-OFF, the participants will start the exercise session with PEMF in ON modality. The PEMF device will be kept ON for 17 minutes. Then, it will be turned OFF while the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect on PEMF at the onset of the exercise. Data acquired in the first 17 minutes (PEMF ON) will be compared with those recorded in the last 17 minutes (PEMF OFF) of the exercise session.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF OFF-ON
Description: In the experimental condition PEMF OFF-ON, the participants will start the exercise session with PEMF in OFF modality. The PEMF device will be kept OFF for 17 minutes. Then, it will be turned ON and the participant will keep going cycling until the end of the trial.~This condition is used to investigate the effect of PEMF during the exercise, when the muscle will have worked for 17 minutes. Data acquired in the first 17 minutes (PEMF OFF) will be compared with those recorded in the last 17 minutes (PEMF ON) of the exercise session.
Study: NCT04836442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol-PTSD-PFI (AP-PFI)
Description: Integrated computer-based personalized feedback intervention to specifically target anxiety sensitivity in the context of hazardous drinking and PTSD symptoms. The AP-PFI will focus on feedback about alcohol behavior in the context of PTSD symptoms, AS, and coping-oriented alcohol use.
Study: NCT06531369

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil Injection（F1 group）
Description: Flumazenil Injection（F1 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flumazenil Injection（F2 group）
Description: Flumazenil Injection（F2 group）: Immediately after surgery, 0.5 mg flumazenil was administered, followed by 0.3 mg flumazenil 25 minutes later.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline（C group）
Description: Flumazenil Injection（F2 group）: Immediately after surgery, an equal volume of saline (equal to the volume of 0.5 mg flumazenil) was administered, followed by an equal volume of saline (equal to the volume of 0.3 mg flumazenil) 25 minutes later.
Study: NCT04836442

Intervention type: OTHER
Group type: OTHER
Intervention: Active Comparison Condition (C-PFI)
Description: Participants in the time-matched comparison condition will receive personalized feedback on alcohol use but will not receive PTSD or AS-related personalized feedback. C-PFI will include alcohol-focused components identical to those provided in AP-PFI (e.g., alcohol profiles, normative feedback). Therefore, it will be possible to isolate the impact of personalized PTSD and AS feedback versus personalized alcohol feedback.
Study: NCT06064292

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSPIRATORY MUSCLE TRAINING
Description: After finishing the 8-week intervention period with IMT, CP patients stopped training with IMT and continued with their daily normal activities. During the following 24 weeks (without IMT), three evaluations of the respiratory parameters analyzed in the trial were made (MIP, MEP, FEV1, PEF). The first evaluation was made 4 weeks after the intervention was completed, the second 12 weeks and the third 24 weeks after finishing IMT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INSPIRATORY MUSCLE TRAINING
Description: After finishing the 8-week intervention period with IMT, CP patients stopped training with IMT and continued with their daily normal activities. During the following 24 weeks (without IMT), three evaluations of the respiratory parameters analyzed in the trial were made (MIP, MEP, FEV1, PEF). The first evaluation was made 4 weeks after the intervention was completed, the second 12 weeks and the third 24 weeks after finishing IMT.
Study: NCT06019520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: Patients in the NAC arm will receive1200 mg of NAC (water-soluble granule Preparation) administered orally once daily at night for 7 consecutive days (1 days before chemotherapy, on the day of chemotherapy, and 5 days after chemotherapy) in each cycle of chemotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Cisplatin-base chemotherapy as per the designated schedule, alongside standard hydration protocol.
Study: NCT05188053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: Single dose administration periarticular 400mg bupivacaine and 12mg meloxicam extended release solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine , epinephrine , ketorolac diluted in sodium chloride
Description: Single dose administration in 100cc of standard formulation, there is 225mg of ropivacaine 5mg/mL, 0.6mg epinephrine 1mg/mL, 30mg ketorolac 30mg/mL diluted in sodium chloride
Study: NCT06450015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Assisted Closure
Description: VAC applied after debridement and saline packing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline Dressing
Description: Wound was managed by saline dressing
Study: NCT05094245

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate Ganglion Block Group
Description: Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.
Study: NCT05237518

Intervention type: DEVICE
Group type: OTHER
Intervention: EarlySense Noomi system
Description: The EarlySense device is intended for continuous contact-free monitoring of heart rate and respiration rate at home, or in professional healthcare settings. The system is intended for remote monitoring of patients by healthcare professionals and is indicated mainly for elderly population monitoring.
Study: NCT06360315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incentive letter for pneumococcal vaccination to the patient and to the GP
Description: Incentive letter for pneumococcal vaccination to the patient and to the GP
Study: NCT06048666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra ovarian by platelet rich plasma
Description: On the day of PRP infusion (within 10 days after completion of menstrual bleeding) we will take 20 cc of venous blood from each participant of group A to prepare PRP. The blood will be transferred to a tube containing sodium citrate and centrifuged at 800 RPM for 15 min and 2000 RPM for 5 min in two stages, respectively. Then, by discarding part of the plasma, PRP will be prepared with a final concentration of one million platelets per microliter. The PRP will be injected into the ovary under spinal anesthesia and a transvaginal ultrasound guide.
Study: NCT06258759

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous platelet-rich plasma supplement
Description: the semen of the additional autologous platelet-rich plasma supplement group will be added by 5% PRP and mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: no autologous platelet-rich plasma supplement
Description: the semen mixed with Sperm Freezing Medium and undergo cryopreservation by Sperm vitrification for 14 days
Study: NCT06131749

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, observational cohort study
Study: NCT04532515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seal-G Surgical Sealant
Description: Seal-G is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seal-G MIST System
Description: Seal-G MIST is a surgical sealant intended for use as an adjunct to standard closure techniques for reinforcement and protection of gastrointestinal anastomoses.~Device is an adjunct device and will be applied following standard colon resection surgery and creation of primary anastomosis
Study: NCT04877860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal rehabilitation program + PNE (Therapeutic exercise, manual therapy and PNE)
Description: The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Finally, patients will have access to the PaiNEd system before the start of the program (to prepare them for treatment sessions) and during the development of the treatment program in which they will introduce their pain levels and their characteristics and also receive a series of educational advice and recommendations for its improvement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal rehabilitation program + traditional biomedical information
Description: The sessions will consist of therapeutic exercise in groups: a) warm-up (10 minutes aerobic exercise), b) active mobilizations (cervical / shoulder) c) strength exercises of the cervical and shoulder muscles + general conditioning d) active postural control e) stretching and relaxation exercises.~4 sessions of myofascial induction.~Patients will receive a dossier with traditional biomedical recommendations on pain management and disability associated with the side effects of cancer treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Waiting list of patients who have agreed to participate in the study. They will receive an information dossier with recommendations on pain control and improvement of dysfunction (similar to what was worked on in the experimental group). These recommendations will be distributed at the beginning of the study (initial assessment) and they will be summoned at 8 weeks for the next collection of variables. All patients will be invited to participate in the experimental phase at the end of the control phase.
Study: NCT06187948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video
Description: All participants in the intervention group watches an informative video on recruitment. This video describes in detail the expected external cephalic version process.
Study: NCT05499780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sentinox
Description: The treatment will be administered in a dose of 0.5 ml into each nostril (5 sprays) per 3 times/day (8 am, 2 pm and 8 pm), for 21 days from Visit 1.
Study: NCT05034341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Prehabilitation
Description: In addition to Standard Clinical Care~Behavioral - An exercise program focusing on aerobic exercise as well as strength training. Sessions will be supervised by a physical therapist, 2 times a week for a minimum of 6-8 weeks in addition to home exercise program. They will also participate in a single session of Cognitive-Behavioral Therapy and will receive an educational pamphlet about Pain and Neuroscience Education.~Dietary Supplement - Protein supplements in the form of protein shakes at a dose of 1.2-1.5 gram per kg daily for 6-8 weeks. Protein supplements will be calculated based on ideal body weight and will be given to the patient with instructions on specific use. Diabetic patients will receive protein supplements that are sugar free.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pre-Surgical Clinical Care
Description: * Education related to preoperative activity and home-based exercise program.~* Standard preoperative consultation with anesthesiology: Preoperative medical optimization and management, referral to medical specialties as deemed necessary with focus on preoperative cognitive assessment.
Study: NCT06242002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Set up of sensor
Description: Surgery is performed as usual for patients needing this medical procedure. At the end, the sensor is set up under the surgical dressing.
Study: NCT05518799

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Patients will receive 2 mg midazolam orally on day 1 of the study and 1 mg midazolam intravenously on day 2 of the study.

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Patients will receive 2 mg midazolam orally on day 1 of the study and 1 mg midazolam intravenously on day 2 of the study.
Study: NCT04861948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI188
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI188
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI188
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI188
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: intravenous
Study: NCT05578482

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dicloxacillin Oral Capsule
Description: Randomized to either systemic dicloxacillin \& elocon or placebo \& elocon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elocon 0.1 % Topical Cream
Description: Both groups are treated with elocon for five days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elocon 0.1 % Topical Cream
Description: Both groups are treated with elocon for five days.
Study: NCT05652972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: 1700 kcal ketogenic diet (fat: protein: carbohydrate ratio of 70:20:10)
Study: NCT04597723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen
Description: Patients will be given different concentrations of oxygen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxygen
Description: Patients will be given different concentrations of oxygen.
Study: NCT06555536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele OI
Description: A data collection and Telemedicine tool translated into an APP.
Study: NCT05250882

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced perioperative care protocol
Description: See arm/group description
Study: NCT05007847

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Apple Watch-based heart rhythm monitoring
Description: For the duration of the study, participants in the active arm will be asked to make ECG recordings in three circumstances:~Routinely once per day from the day of randomisation till the 12-month visit after AF Catheter Ablation (they will be encouraged to do so at the same time each day with the option to set a reminder on the watch).~If the AW requests them to do so (the automatic AF-notification algorithm will be active throughout the study period and if AF is suspected based on the tachogram, it will trigger notification for the participant to make an ECG recording). This will be till the 12-month time point.~If the patient has symptoms of palpitations, pre-syncope or syncope. This will be till the 12-month time point. Monitoring should continue even if AF has been diagnosed to characterise arrhythmia burden and profile. Participants will be given the contact details of a dedicated email inbox to which to send ECGs recorded through the AW.
Study: NCT05865821

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Negative pressure drainage
Description: Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure

Intervention type: OTHER
Group type: OTHER
Intervention: No pressure drain
Description: Negative pressure drainage is a drainage catheter which is placed in subcutaneous surgical wound for draining fluid such as hematoma, seroma, and pus. In this study the drainage the catheter will be placed in the wound for 5 days and/or removed if fluid content is less than 20 ml per day. Jackson-Pratt catheter or Redivac is used in this study because it is cheap and widespread in all hospitals. The drainage catheter is placed after completion of surgery and before skin closure